However, although such antagonists are used as pharmaceuticals, none is approved for obesity treatment to date or has been reported for significant weight loss in humans.5 Nevertheless, since activation of NK1R might still result in increased weight gain, specific targeting of NK2R is essential. The gene discussed is TACR2; the disease is obesity due to melanocortin 4 receptor deficiency.